摘要
为评价泰素加卡铂联合化疗治疗晚期与复发性上皮性卵巢癌的疗效 ,对 2 3例采用泰素加卡铂治疗患者的疗效进行分析。 14例初治晚期患者采用泰素加卡铂方案一线化疗 ,有效 12例 ,完全缓解 12例 ,2年无瘤存活者 10例。 9例复发患者采用泰素加卡铂方案二线化疗 ,有效 4例 ,完全缓解 2例 ,部分缓解 2例。该方案主要副反应为骨髓抑制和关节肌肉痛。提示
To investigate the effect of combined chemotherapy of paclitaxel and carboplatin(TP)for advanced and recurrent epithelial ovarian cancer, the curative effects of 23 patients treated with a combined chemotherapy of TP after cytoreductive surgery were analyzed. Among 14 advanced patients who were subject to TP as first line regimen, 12 were complete response, 10 patients were 2 year survival free of tumor. In the remaining 9 recurrent patients with TP as second line regimen, 4 patients obtained overall response: 2 complete response and 2 partial response. The major side effects were toxicity neutropenia and arthromyalgia. The results suggest the TP regimen should be chosen as preferred first line regimen in advanced epithelial ovarian cancer.
出处
《华中科技大学学报（医学版）》
CAS
CSCD
北大核心
2002年第4期418-419,共2页
Acta Medicinae Universitatis Scientiae et Technologiae Huazhong
基金
国家自然科学基金资助项目 (No.39870 76 5 )
关键词
上皮性卵巢癌
泰素
卡铂
联合化疗
治疗
epithelial ovarian cancer
paclitaxel
carboplatin
combined chemotherapy
